Literature DB >> 14767300

Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement.

M J Drake1, I W Mills, J G Noble.   

Abstract

PURPOSE: Nocturia is a common condition often attributed in aging men to benign prostatic enlargement. Older adults are prone to nocturnal sleep disturbance, of which disturbed circadian rhythm may be a component since it improves with nighttime administration of melatonin. This study was designed to investigate melatonin as a potential treatment for nocturia associated with bladder outflow obstruction in older men.
MATERIALS AND METHODS: A total of 20 men with urodynamically confirmed bladder outflow obstruction and nocturia were entered into a randomized, double blind, placebo controlled crossover study assessing the effect of 2 mg controlled release melatonin at night on nocturia. Symptoms were assessed at baseline and after each 4-week treatment period using a frequency volume chart, the International Prostate Symptom Score and symptom problem index. Maximum urinary flow rate and post-void residual urine volume were also assessed.
RESULTS: Baseline frequency of nocturia was 3.1 episodes per night. There were 7 men (35%) with detrusor overactivity and 10 (50%) had nocturnal polyuria. Melatonin and placebo caused a decrease in nocturia of 0.32 and 0.05 episodes per night (p = 0.07) and a decrease in the nocturia bother score of 0.51 and 0.05, respectively (p = 0.008). Nocturia responder rates (a reduction from baseline of at least -0.5 episodes per night) differed between the active medication and placebo groups (p = 0.04). Daytime urinary frequency, International Prostate Symptom Score, relative nocturnal urine volume, maximum urinary flow rate and post-void residual were unaffected by melatonin treatment.
CONCLUSIONS: Melatonin treatment is associated with a significant nocturia response rate, improvement in nocturia related bother and a good adverse effect profile. However, it is uncertain whether the observed changes in this study are clinically significant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767300     DOI: 10.1097/01.ju.0000110442.47593.ea

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  Managing nocturia.

Authors:  Serge P Marinkovic; Lisa M Gillen; Stuart L Stanton
Journal:  BMJ       Date:  2004-05-01

2.  Nocturia: Evaluation and Current Management Strategies.

Authors:  Casey G Kowalik; Joshua A Cohn; Sophia Delpe; W Stuart Reynolds; Melissa R Kaufman; Doug F Milam; Alan J Wein; Roger R Dmochowski
Journal:  Rev Urol       Date:  2018

Review 3.  Pharmacotherapy for nocturia in the elderly patient.

Authors:  Ragnar Asplund
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  The dilemma of nocturia.

Authors:  Marcus J Drake
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

Review 5.  Nocturia: aetiology and treatment in adults.

Authors:  Hasan Dani; Ashanda Esdaille; Jeffrey P Weiss
Journal:  Nat Rev Urol       Date:  2016-07-26       Impact factor: 14.432

Review 6.  Nocturia: Current Evaluation and Treatment for Urology.

Authors:  Tony Nimeh; Pedro Alvarez; Naem Mufarreh; Lori B Lerner
Journal:  Curr Urol Rep       Date:  2015-09       Impact factor: 3.092

7.  Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.

Authors:  Yun Seob Song; Ja Hyeon Ku
Journal:  Int Urol Nephrol       Date:  2007-07-03       Impact factor: 2.370

Review 8.  Melatonin and Its Role in Lower Urinary Tract Function: An Article Review.

Authors:  Ali Fathollahi; Firouz Daneshgari; Ann T Hanna-Mitchell
Journal:  Curr Urol       Date:  2015-09-04

Review 9.  Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?

Authors:  Amit Batla; Véronique Phé; Lorenzo De Min; Jalesh N Panicker
Journal:  Mov Disord Clin Pract       Date:  2016-06-07

10.  Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.

Authors:  Takashi Kawahara; Satoshi Morita; Hiroki Ito; Hideyuki Terao; Ryoko Sakata; Hitoshi Ishiguro; Katsuyuki Tanaka; Hiroshi Miyamoto; Junichi Matsuzaki; Yoshinobu Kubota; Hiroji Uemura
Journal:  BMC Urol       Date:  2013-06-12       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.